Proactive Investors - Run By Investors For Investors

Breakfast News - MC Mining, Inspiration Healthcare Group, Netscientific and more..

Breakfast News - MC Mining, Inspiration Healthcare Group, Netscientific and more..

Set menu


AIM:


Total number of AIM Companies (Incl Susp):

 

905*

 

Total number of AIM Companies trading:

 

835*

 

*as at close of business  11 March 2019

 

Standard List**  of Main Market:

 

Total number of Standard List Companies

 

(Incl Susp):

 

161*

 

Total number of Standard List Companies trading:

 

142*

 

*as at close of business 11 March 2019

 

NEX Growth Market:

 

Total number of NEX Growth Market Companies (Incl Susp):

 

89*

 

Total number of NEX Growth Market Companies trading:

 

87*               

 

*as at close of business 11 March 2019

 

*A corporate client of Hybridan LLP

 

**  Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity

 

Dish of the day

 

No Joiners Today

 

Off the menu      

 

No Leavers Today

 

What’s cooking in the IPO kitchen?

 

Main Market (Premium)

 

US Solar Fund, a newly-established investment company focused on investing in solar power assets mainly in the US, looking to raise $250m at $1. Expected 20 March

 

AIM

 

Techniplas –global  producer and support services company providing highly engineered and technically complex components, making the supply chain to original equipment manufacturers more efficient.  FYDec17 rev $515m.

 

Diaceutics, a data analytics and implementation services company which services the global pharmaceutical industry, is looking to join AIM late March, offer TBC.

 

Rumours & Speculation

 

Proactive Investors reports that London-based investment management firm M12 Global. intends to list  “on one of the main London stock exchanges later this year to fill over $3bn worth of demand for credit within the Mayfair 101 portfolio over the next five years.”

 

Banquet Buffet

 

Safe Harbour Holdings (LON:SHH) 132.5p £36.11m

 

Appointment of James Brotherton as CFO and an Executive Director of the Company effective on 1 Aug 2019.

 

James joins Safe Harbour from Tyman plc, where he has been CFO since 2010. Tyman is a leading international supplier of engineered components to the door and window industry, and has more than doubled in size and profitability during James' tenure as CFO.

 

While in his executive role with Tyman plc, James delivered and successfully integrated numerous acquisitions across multiple jurisdictions that have created significant value for Tyman shareholders as part of Tyman's international growth strategy.

 

Safe Harbour is a company established with the objective of creating a global leader in B2B distribution and/or business services. 

 

MC Mining (LON:MCM) 45.5p £64.1m

 

Commencing  developm­ent of its flagship Makhado hard coking and thermal coal project .

 

Construction to commence in Q3 CY2019 if all conditions satisfied

 

nine-month construction period

 

commence mining at west pit producing ~3m tonnes per annum ("Mtpa") of run-of-mine ("ROM") coal

 

ROM coal partially beneficiated prior to despatch to the modified Vele Colliery for processing

 

~1.1Mtpa of saleable coal produced (at steady state):

 

~0.54Mtpa of hard coking coal ("HCC")

 

~0.57Mtpa of 5,500kcal thermal coal

 

internal rate of return  in excess of 45%

 

peak funding payback of less than 2.5 years

 

Avesoro Resources (ASO.L) 153.5p £125.22m

 

FY Dec 18 results.

 

2018 gold production of 220,458 ounces,

 

Consolidated operating cash costs of $774 per ounce sold and all-in sustaining costs ("AISC") of $1,043 per ounce sold1;

 

Company revenues of $282.8m, an increase of 189% year on year (driven by gold sales of 220,998 ounces, a 186% increase YoY at an average realised gold price of $1,275 per ounce, a 1% increase YoY;

 

Company EBITDA of $77.5m, an increase of 348% YoY and EBITDA margin of 27%;

 

Total capex of $44.7m, including $6.5m exploration expenditure and $23.2m on additional heavy mining equipment and $15m on capitalised waste stripping; and

 

Gross Debt of $127m, a reduction of 5% YoY.

 

Inspiration Healthcare Group (LON:IHC) 63.5p £19.47m

 

“The global medical device company, announced that it has agreed financial terms to start the shipment of almost 500 AlphaCore5 Patient Warming Systems to Poland's largest non-governmental, and non profit charity, The Great Orchestra of Christmas Charity (GOCC), via our local distributor.

 

The AlphaCore5 Patient Warming System is designed for use in operating theatres, delivery suites, and neonatal intensive care units. The order will be shipped during the next two months to over 200 hospitals for treating newborn babies throughout Poland where the Group has had a long term distributor relationship. This is the largest single order ever  received for patient warming systems by the Group.”

 

PPHE Hotel (LON:PPH) 1750p £741m

 

JV agreement with Largo 542 West 29th Street Partners LLC, an affiliate of Largo,  New York based real estate development and investment firm, to acquire properties located at 538, 540 and 542 West 29th Street, New York. The aggregated consideration for the acquisition of the Property was $42m plus associated acquisition costs.

 

The JV intends to develop a mixed-use scheme consisting of a 98-room art'otel® branded hotel with extensive public areas and 55 residential condominium units (the "Project"). PPHE and Largo each hold a 50% interest in the JV and, once the hotel is operational, PPHE will manage it under a management contract.

 

Impellam Group (LON:IPEL) 468p £230.5m

 

FYJan 19 Prelims from the managed services and specialist staffing brand. Revs up 4.9% driven by managed services.  Ongoing strategic IT investments, the increased cost of doing business compliantly and the downturns in the markets resulted in adjusted EBITDA of £50.2m (2017: £59.5m). 

 

Net debt down 5.5% to £71.7m. “Looking forward, we anticipate continued market and technological disruption and downward pricing pressure, as well as ongoing uncertainty from Brexit. Notwithstanding this, we anticipate an increasing return from our strategic investments in 2019”.

 

Global Invacom (LON:GINV) 5.2p £13.5m

 

The global provider of satellite communications equipment, announced a partnership with Edgewater Wireless Systems Inc (YFI: TSX.V) (OTCQB: KPIFF), for the further development of Broadcast WiFi ("Bx-WiFi"), a technology that enables live, high quality and large-scale event video streaming over a Wi-Fi network.

 

Edgewater is an industry leader in innovative WiFi Multi-Channel Single Radio technology for residential and commercial markets. The Partnership will leverage Edgewater's expertise to further develop the existing Bx-WiFi technology and will provide access to Edgewater's professional grade WiFi technology, engineered to support high-client density applications. Access to Edgewater's MCSR™ platform will enable large scale testing over a high-quality network designed to withstand increasing use of WiFi and mobile devices within stadiums and arenas.

 

Oakley Capital Investments (LON:OCI) 188p £385m

 

OCI which provides its shareholders with access to a portfolio of high quality companies through its investments in the Oakley Funds2, announced its annual results for the year ended 31 Dec 2018

 

NAV per share of £2.81, a total return of 16%

 

Total NAV of £574.8m, a 5-year CAGR of 18%

 

Final dividend of 2.25p per share, payable in April 2019 (full year dividend of 4.5p)

 

£130.8m of capital was deployed and £165.8m cash was returned to the Company

 

Netscientific (LON:NSCI) 14.9p £11.12m

 

NSCI notes its recent share price movement and confirms that it is not aware of any reason for such movement.

 

Furthermore, the Company notes, that despite the increase in share price over recent days, the current share price still represents a substantial discount to the share price prior to announcing the update to the Strategic Review on 20 Dec 2018.

 

NetScientific identifies, commercialises, source, develop and manage Diagnostics, Digital Health, Biomedical, Therapeutics and Technologies Companies.

 

 

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use